IFRX InflaRx N.V. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

IFRX [NASD]

InflaRx N.V.

Healthcare | Biotechnology | Germany

statements

Index	-	P/E	-	EPS (ttm)	-2.24	Insider Own	33.78%	Shs Outstand	26.11M	Perf Week	3.18%
Market Cap	130.91M	Forward P/E	-	EPS next Y	-1.38	Insider Trans	0.00%	Shs Float	17.19M	Perf Month	-33.65%
Income	-58.30M	PEG	-	EPS next Q	-0.43	Inst Own	20.00%	Short Float	3.98%	Perf Quarter	-3.56%
Sales	-	P/S	-	EPS this Y	-72.40%	Inst Trans	-3.29%	Short Ratio	0.77	Perf Half Y	21.14%
Book/sh	4.39	P/B	1.11	EPS next Y	7.60%	ROA	-	Target Price	8.24	Perf Year	48.48%
Cash/sh	4.52	P/C	1.08	EPS next 5Y	-	ROE	-	52W Range	2.17 - 9.70	Perf YTD	22.98%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-49.78%	Beta	-
Dividend %	-	Quick Ratio	9.50	Sales past 5Y	-	Gross Margin	-	52W Low	124.42%	ATR	0.56
Employees	38	Current Ratio	9.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.75	Volatility	10.77% 9.39%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	16.80%	Profit Margin	-	Rel Volume	0.34	Prev Close	5.04
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 21 BMO	Payout	-	Avg Volume	888.73K	Price	4.87
Recom	2.90	SMA20	-8.95%	SMA50	-27.64%	SMA200	12.29%	Volume	299,978	Change	-3.37%

Jun-17-20

Initiated

BTIG Research

Buy

$12

Apr-30-20

Upgrade

Raymond James

Mkt Perform → Outperform

Jun-05-19

Downgrade

SunTrust

Buy → Hold

$55 → $5

Jun-05-19

Downgrade

Robert W. Baird

Outperform → Neutral

$58 → $6

Jun-05-19

Downgrade

JP Morgan

Overweight → Underweight

$67 → $9

Jun-05-19

Downgrade

Guggenheim

Buy → Neutral

$65 → $6

Jun-05-19

Downgrade

BMO Capital Markets

Outperform → Market Perform

Jan-29-19

Initiated

Robert W. Baird

Outperform

Dec-10-18

Initiated

Credit Suisse

Outperform

Jul-13-18

Initiated

BMO Capital Markets

Outperform

$45

Jun-28-18

Initiated

SunTrust

Buy

$55

Jun-28-18

Initiated

Raymond James

Outperform

Feb-08-18

Initiated

B. Riley FBR, Inc.

Buy

$40

Jul-09-20 07:33AM	InflaRx Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-25-20 04:05PM	Hedge Funds Are Buying InflaRx N.V. (IFRX) Insider Monkey
Jun-17-20 07:30AM	InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19 GlobeNewswire -25.07%
Jun-11-20 08:30AM	InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions Zacks -11.17%
May-29-20 11:10AM	The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin Zacks
May-28-20 08:31AM	Europe Equities Are Hot on Stimulus Optimism: 5 Picks Zacks +7.05%
May-21-20 07:30AM	InflaRx Reports Q1 2020 Financial & Operating Results GlobeNewswire +7.77%
Apr-29-20 08:00AM	InflaRx Reports Full Year 2019 Financial & Operating Results GlobeNewswire -6.55%
Apr-14-20 07:30AM	We're Hopeful That InflaRx (NASDAQ:IFRX) Will Use Its Cash Wisely Simply Wall St.
Apr-01-20 04:18PM	Covid Report: Testing News Sends One Biotech Flying As Another Dives Investor's Business Daily +50.00%
07:38AM	The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests Benzinga
Mar-31-20 04:15PM	InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology GlobeNewswire +8.22%
Mar-06-20 10:49AM	4 Smaller, Cash-Rich Biotech Stocks That Could Be Havens Barrons.com +7.45%
Feb-26-20 07:30AM	InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum GlobeNewswire +16.03%
Feb-19-20 08:00AM	InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference GlobeNewswire +13.84%
Jan-09-20 07:30AM	InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference GlobeNewswire +5.51%
Dec-20-19 07:45PM	Did Hedge Funds Drop The Ball On InflaRx N.V. (IFRX) ? Insider Monkey
Nov-07-19 07:30AM	InflaRx Reports Third Quarter 2019 Financial & Operating Results ACCESSWIRE +5.79%
07:18AM	The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
02:10AM	InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa ACCESSWIRE
Oct-17-19 08:43AM	Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation Simply Wall St.
Aug-14-19 04:05PM	InflaRx Reports Second Quarter 2019 Financial & Operating Results GlobeNewswire
Jul-19-19 12:43PM	Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)? Simply Wall St.
Jul-18-19 04:01PM	InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa GlobeNewswire
09:55AM	InflaRx Enters Oversold Territory Zacks
Jun-29-19 11:31PM	Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) Insider Monkey
Jun-13-19 10:18AM	InflaRx Enters Oversold Territory Zacks
09:00AM	InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum GlobeNewswire
Jun-05-19 04:18PM	InflaRx shares plummet over 90% after drug test failure Yahoo Finance Video -91.79%
07:49AM	InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa GlobeNewswire
May-23-19 09:15AM	InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates Zacks
08:00AM	InflaRx Reports First Quarter 2019 Financial & Operating Results GlobeNewswire
May-14-19 08:00AM	InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe GlobeNewswire
May-03-19 10:12AM	Did Hedge Funds Drop The Ball On InflaRx N.V. (IFRX)? Insider Monkey
Apr-10-19 08:45AM	InflaRx (IFRX) Catches Eye: Stock Jumps 7.5% Zacks +7.38%
Mar-28-19 08:30AM	InflaRx Full Year 2018 Financial & Operating Results GlobeNewswire
Mar-12-19 07:37AM	InflaRx (NASDAQ:IFRX) Shareholders Booked A 63% Gain In The Last Year Simply Wall St.
Feb-27-19 08:30AM	InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum GlobeNewswire +5.81%
Feb-25-19 07:30AM	Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-14-19 08:30AM	Richard Brudnick to Join InflaRx Board of Directors GlobeNewswire
Feb-06-19 07:00AM	InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa GlobeNewswire
Jan-03-19 08:30AM	InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management GlobeNewswire
Dec-22-18 03:43AM	Is InflaRx N.V. (IFRX) A Good Stock To Buy? Insider Monkey
Dec-19-18 08:30AM	InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis GlobeNewswire
Nov-21-18 08:30AM	InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results GlobeNewswire +7.23%
Nov-08-18 02:30AM	InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa GlobeNewswire +8.06%
Oct-30-18 07:30AM	InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing GlobeNewswire
Oct-23-18 09:15AM	Factors of Influence in 2018, Key Indicators and Opportunity within Dropbox, Kura Oncology, DHT, Wayfair, US Foods Holding, and InflaRx N.V New Research Emphasizes Economic Growth GlobeNewswire
Sep-21-18 08:30AM	InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors GlobeNewswire
Aug-28-18 07:30AM	InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1 GlobeNewswire +5.02%
Aug-09-18 07:00AM	InflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results GlobeNewswire
Jun-28-18 07:30AM	InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis GlobeNewswire
Jun-05-18 07:30AM	InflaRx Opens New Research Facility in Ann Arbor GlobeNewswire
May-17-18 07:30AM	InflaRx N.V. Reports First Quarter 2018 Financial & Operating Results GlobeNewswire
May-08-18 10:42AM	InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shares GlobeNewswire
May-03-18 08:28PM	InflaRx N.V. Announces Pricing of Primary and Secondary Offering of Common Shares GlobeNewswire -7.05%
May-02-18 07:44AM	InflaRx N.V. Announces Proposed Primary and Secondary Offerings of Common Shares GlobeNewswire -6.54%
Mar-29-18 07:00AM	InflaRx Full Year 2017 Financial & Operating Results GlobeNewswire
Mar-12-18 08:40AM	Blog Exposure - InflaRx Enrolled First Patient in Phase-IIb Trial of Lead Candidate IFX-1 in Hidradenitis Suppurativa ACCESSWIRE +7.98%
Mar-08-18 08:23AM	InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa Business Wire
Feb-06-18 07:52AM	InflaRx Announces Appointment of Tony Gibney to Its Board of Directors Business Wire
Feb-01-18 09:55AM	InflaRx Presents at Two Scientific Conferences in February, 2018 Business Wire
Jan-23-18 01:53PM	Breaking Down InflaRx NVs (NASDAQ:IFRX) Ownership Structure Simply Wall St.
Jan-15-18 10:51AM	What Can We Expect for InflaRx NV (NASDAQ:IFRX) Moving Forward? Simply Wall St.
Jan-09-18 08:56AM	InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa Business Wire
Jan-04-18 01:47PM	InflaRx to Present at Upcoming Investor Conferences Business Wire +13.56%
08:00AM	InflaRx NV (NASDAQ:IFRX): Are Analysts Bull Or Bear? Simply Wall St.
Nov-10-17 08:05AM	The Biotech IPO Boom Will Continue, Nasdaq Execs Predict Forbes
Nov-08-17 01:31PM	InflaRX NV (Nasdaq: IFRX) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience